Biochaperone Combo

Phase 3Small molecule

Biochaperone Combo is one of 130 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Diabetic FootActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Type 2 DiabetesPhase 1

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Diabetic FootPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Biochaperone Combo

AAdocia

Phase 3

3 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 8

Sglt2i

UUniversity of Chicago

Preclinical

2 9

Glucagon-Like Peptide-1 (GLP-1)

Novo Nordisk

Preclinical

1 10

BQ123

VVanderbilt University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes4 trials

A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 1·NCT02029924·37 enrolled

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 2·NCT02146651·38 enrolled

A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 1/2·NCT02213146·38 enrolled

Show 1 more trial

A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 1·NCT01981031·21 enrolled

Type 2 Diabetes3 trials

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02514850·24 enrolled

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT03180710·32 enrolled

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02915250·36 enrolled

Trial3 trials

A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM

Completed·AAdocia·Phase 1/2·NCT02739906·36 enrolled

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Completed·AAdocia·Phase 1·NCT03179332·43 enrolled

A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Completed·AAdocia·Phase 1·NCT03176524·27 enrolled

Type 1 Diabetes Mellitus2 trials

To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT02528396·36 enrolled

Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT02514954·28 enrolled

Diabetic Foot1 trial

A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer

Completed·AAdocia·Phase 3·NCT02236793·252 enrolled

5 more indications

MPA1 trial

Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal

Completed·AAdocia·Phase 1·NCT02344992·38 enrolled

Infusion1 trial

A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®

Completed·AAdocia·Phase 1·NCT02562313·80 enrolled

Clinical Trial1 trial

A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers

Completed·AAdocia·Phase 1·NCT02529293·26 enrolled

Single Dose1 trial

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Completed·AAdocia·Phase 1·NCT02660502·15 enrolled

Type 2 Diabetes Mellitus1 trial

A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT02562326·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Biochaperone Combo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biochaperone Combo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biochaperone Combo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adocia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdocia

Biochaperone Combo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes4 trials

Type 2 Diabetes3 trials

Trial3 trials

Type 1 Diabetes Mellitus2 trials

Diabetic Foot1 trial

MPA1 trial

Infusion1 trial

Clinical Trial1 trial

Single Dose1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News